TCM
GTHX

Tuttle Capital Management’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Tuttle Capital Management’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-44,173
Closed -$1.6M – 262
2019
Q3 		$1.6M Buy
+44,173
New +$1.39M 0.43% 73

Other funds holding GTHX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Tuttle Capital Management's GTHX Position: Q4 2019 in Review

Tuttle Capital Management sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q4 2019, closing a stake of 44,173 shares — an estimated $1.6M sold.

Tuttle Capital Management first reported a position in GTHX in Q3 2019 and held it in 1 quarter. The position peaked at $1.6M in Q3 2019. 98 funds tracked by Wall St. Rank hold GTHX as of Q4 2019.

  • Tuttle Capital Management reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Tuttle Capital Management sold 44,173 G1 Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $1.6M.
  • Tuttle Capital Management first reported a position in G1 Therapeutics, Inc. Common Stock in Q3 2019 and held it in 1 quarter.
  • Tuttle Capital Management's G1 Therapeutics, Inc. Common Stock position peaked at $1.6M in Q3 2019.
  • 98 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Tuttle Capital Management's 13F filing for Q4 2019, filed 13 Jan 2020.